Bicalutamide
- Generic Name
- Bicalutamide
- Brand Names
- Casodex
- Drug Type
- Small Molecule
- Chemical Formula
- C18H14F4N2O4S
- CAS Number
- 90357-06-5
- Unique Ingredient Identifier
- A0Z3NAU9DP
- Background
Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor.
- Indication
Bicalutamide is indicated in combination with a luteinizing hormone-releasing hormone (LHRH) agonist for the treatment of Stage D2 metastatic carcinoma of the prostate.
- Associated Conditions
- Metastatic stage D2 Prostatic carcinoma
- Associated Therapies
- -
SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer
- Conditions
- Interventions
- Drug: AZD2014Drug: AnthracyclinesDrug: MEDI4736Drug: AZD4547Drug: TaxanesDrug: AZD5363Drug: cyclophosphamideDrug: DNA intercalatorsDrug: AZD8931Drug: SelumetinibDrug: MethotrexateDrug: vinca alkaloidsDrug: VandetanibDrug: Platinum based chemotherapiesDrug: BicalutamideDrug: OlaparibDrug: BevacizumabDrug: Mitomycin CDrug: Eribulin
- First Posted Date
- 2014-11-24
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 1460
- Registration Number
- NCT02299999
- Locations
- 🇫🇷
Hopitaux Universitaire de Strasbourg - Hopital Civil, Strasbourg, France
🇫🇷Institut Claudius Regaud, Toulouse, France
🇫🇷Hopitaux Du Leman, Thonon-les-Bains, France
A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer
- First Posted Date
- 2014-03-12
- Last Posted Date
- 2019-06-28
- Lead Sponsor
- Takeda
- Target Recruit Count
- 116
- Registration Number
- NCT02085252
- Locations
- 🇫🇷
Ouzid, Paris La Défense,, Paris, France
🇫🇷Tenon Hospital Paris France, Paris, France
Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate
- Conditions
- Interventions
- First Posted Date
- 2014-02-17
- Last Posted Date
- 2022-10-18
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 17
- Registration Number
- NCT02064036
- Locations
- 🇺🇸
UC Davis Sacramento Cancer Center Dept of Radiation Oncology, Sacramento, California, United States
A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-02-11
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 72
- Registration Number
- NCT02059213
- Locations
- 🇺🇸
Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸University of Michigan Hospital, Ann Arbor, Michigan, United States
LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer
- First Posted Date
- 2014-02-10
- Last Posted Date
- 2023-05-10
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 71
- Registration Number
- NCT02058706
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Henry Ford Hospital, Detroit, Michigan, United States
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer
- First Posted Date
- 2013-03-13
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 1313
- Registration Number
- NCT01809691
- Locations
- 🇺🇸
Los Angeles County-USC Medical Center, Los Angeles, California, United States
🇺🇸USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-02-07
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 310
- Registration Number
- NCT01786265
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Degarelix Neo-Adjuvant Radical Prostatectomy Trial
- Conditions
- Interventions
- First Posted Date
- 2012-08-28
- Last Posted Date
- 2015-12-22
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 35
- Registration Number
- NCT01674270
- Locations
- 🇨🇦
Vancouver General Hospital, Vancouver, British Columbia, Canada
🇨🇦University Health Network, Toronto, Ontario, Canada
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
- First Posted Date
- 2012-08-14
- Last Posted Date
- 2019-01-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 396
- Registration Number
- NCT01664923
- Locations
- 🇺🇸
Alliance Urology Specialists, PA, Greensboro, North Carolina, United States
🇺🇸John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸UCLA Clark Urology Clinic, Los Angeles, California, United States
TAK-700 in Castration Resistant Prostate Cancer
- Locations
- 🇧🇪
Cliniques Universitaires Saint-Luc, Brussels, Belgium
🇧🇪Onze Lieve Vrouw Ziekenhuis, Aals, Belgium
🇧🇪AZ Groeninge Kortrijk - Campus Vercruysselaan, Kortrijck, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.